Abstract: A circuit includes a memory cell column coupled to a bit line pair and a write circuit that alternately biases a first end of the bit lines toward power supply and reference voltage levels in a write operation. Each of first and second switching circuits at second ends of the bit lines includes first and second logic circuits, each including an input terminal coupled to a corresponding bit line, and first and second switching devices, each including a gate coupled to the corresponding logic circuit. The first logic circuit and switching device couple the corresponding bit line to a power supply node simultaneously with the write circuit biasing the corresponding bit line toward the power supply voltage level, and the second logic circuit and switching device couple the corresponding bit line to a reference node simultaneously with the write circuit biasing the corresponding bit line toward the reference voltage level.

Abstract: Disclosed herein are related to an integrated circuit including a semiconductor layer. In one aspect, the semiconductor layer includes a first region, a second region, and a third region. The first region may include a circuit array, and the second region may include a set of interface circuits to operate the circuit array. A side of the first region may face a first side of the second region along a first direction. The third region may include a set of header circuits to provide power to the set of interface circuits through metal rails extending along a second direction. A side of the third region may face a second side of the second region along the second direction. In one aspect, the first side extending along the second direction is shorter than the second side extending along the first direction, and the metal rails are shorter than the first side.

Abstract: A fusion protein for use as a hepatitis B therapeutic vaccine is disclosed. The fusion protein comprises: (a) an antigen-presenting cell (APC)-binding domain or a CD91 receptor-binding domain; (b) a protein transduction domain; and (c) an antigen comprising a hepatitis B virus X protein deletion mutant that lacks amino acids (aa) at least from as 21 to as 50. The protein transduction domain is a fusion polypeptide comprising a T cell sensitizing signal-transducing peptide, a linker, and a translocation peptide. The APC-binding domain or the CD91 receptor-binding domain is located at the N-terminus of the fusion protein, and the antigen is located at the C-terminus of the protein transduction domain.

Abstract: A fusion protein for use as a hepatitis B therapeutic vaccine is disclosed. The fusion protein comprises: (a) an antigen-presenting cell (APC)-binding domain or a CD91 receptor-binding domain; (b) a protein transduction domain; and (c) an antigen comprising a hepatitis B virus X protein deletion mutant that lacks amino acids (aa) at least from as 21 to as 50. The protein transduction domain is a fusion polypeptide comprising a T cell sensitizing signal-transducing peptide, a linker, and a translocation peptide. The APC-binding domain or the CD91 receptor-binding domain is located at the N-terminus of the fusion protein, and the antigen is located at the C-terminus of the protein transduction domain.

Abstract: A method for synthesizing polyhydroxyalkanoate using a microorganism includes providing a Ralstonia eutropha strain; providing a fermentation tank and adding crude glycerol into the fermentation tank; adding a nitrogen source into the fermentation tank to adjust a carbon to nitrogen (C/N) ratio to 20:1 to 150:1; controlling temperature of the fermentation tank to a temperature ranging from 20 to 45° C.; adding 5 to 20% by volume of the Ralstonia eutropha strain into the fermentation tank using a mixing speed of from 100 to 500 rpm, an aeration quantity of 0.5-2 vvm and a concentration of dissolved oxygen of 30 to 80%; fermenting contents of the fermentation tank for 48 to 96 hours to allow the Ralstonia eutropha strain to proliferate and to allow polyhydroxyalkanoate to be synthesized from the crude glycerol within cells of the Ralstonia eutropha strain; and disrupting the cells of the Ralstonia eutropha strain and extracting polyhydroxyalkanoate.

Abstract: A system for integrated information service is provided. The system of integrated information service comprises an interface, a first storage device, a second storage device, and a processor. The interface receives query information for manufacturing information. The first storage device stores manufacturing information from a plurality of separate data sources corresponding to different stages of manufacture of semiconductor devices. The second storage device stores configuration data for information service pertaining to each of the data sources corresponding to different stages of manufacturing. The processor provides information service according to the query information, the configuration data, and the manufacturing information.